References
- Labrie F, Dupont A, Belanger A, et al. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate 1983; 4: 579–94
- Crawford E D, Eisenberg M A, McLeod D G, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419–24
- Poyet P, Labrie F. Comparison of the antiandrogenic/androgenic activities of flutamide, cyproterone acetate and megestrol acetate. Mol Cell Endocrinol 1985; 42: 283
- Labrie C, Cusan L, Plante M, Lapointe S, Labrie F. Analysis of the androgenic activity of synthetic ‘progestins’ currently used for the treatment of prostate cancer. J Steroid Biochem 1987; 28: 379
- Figg W D, Sartor O, Cooper M R, et al. Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 1995; 98: 412–4
- Scher H I, Kelly W K. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 1566–72
- Gaddipati J P, McLeod D G, Heidenberg H B, et al. Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers. Cancer Res 1994; 54: 2861–4
- Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J Steroid Biochem 1993; 46: 759–65
- Figg W D, McCall N A, Reed E, Sartor O. The in vitro response of four antisteroid receptor agents on the hormone-responsive prostate cancer cell line LNCaP. Oncol Reports 1995; 2: 1–4
- Wilding G, Chen M, Gelman E P. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14: 103–15
- Veldscholte J, Ris-Stalpers C, Kuiper G GJM, et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochem Biophys Res Commun 1990; 173: 534–40
- Taplin M E, Bubley G, Shuster T D, et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995; 332: 1393–8
- Haynes R C. Andrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. Goodman and Gilman's The Pharmacological Basis of Therapeutics, A G Gillman, T W Rail, A S Nies, P Taylor. Pergamon Press, New York 1990; 1458–9
- Kelly W K, Scher H I, Mazumdar M, Vlamis V, Schwartz M, Fossa S D. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 1993; 11: 607–15
- Sartor O, Cooper M, Weinberger M, et al. Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of ‘hormone refractory’ prostate cancer. J Natl Cancer Inst 1994; 86: 222–7
- Dawson N A, Cooper M R, Figg W D, et al. Activity of suramin in hormone-refractory prostate cancer is diminished when hydrocortisone and flutamide withdrawal are removed as potential confounding variables. Cancer 1995; 76: 453–62
- Dupont A, Gomez J L, Cusan L, Koutsilieris M, Labrie F. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150: 908–13